{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T08:48:27Z","timestamp":1788425307796,"version":"build-2803163510"},"reference-count":150,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["gimjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genetics in Medicine"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.gim.2022.12.005","type":"journal-article","created":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T09:05:11Z","timestamp":1689843911000},"page":"100358","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Phenylalanine hydroxylase deficiency treatment and management: A systematic evidence review of the American College of Medical Genetics and Genomics (ACMG)"],"prefix":"10.1016","volume":"25","author":[{"given":"April D.","family":"Adams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mois\u00e9s \u00d3.","family":"Fiesco-Roa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle P.","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Malinowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia M.","family":"Demarest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Rothberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith A.","family":"Hobert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.gim.2022.12.005_bib1","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ajhg.2020.06.006","article-title":"The genetic landscape and epidemiology of phenylketonuria","volume":"107","author":"Hillert","year":"2020","journal-title":"Am J Hum Genet"},{"issue":"9750","key":"10.1016\/j.gim.2022.12.005_bib2","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(10)60961-0","article-title":"Phenylketonuria","volume":"376","author":"Blau","year":"2010","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.gim.2022.12.005_bib3","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/gim.2013.157","article-title":"Phenylalanine hydroxylase deficiency: diagnosis and management guideline","volume":"16","author":"Vockley","year":"2014","journal-title":"Genet Med"},{"issue":"6","key":"10.1016\/j.gim.2022.12.005_bib4","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1542\/peds.2013-1441","article-title":"The political history of PKU: reflections on 50 years of newborn screening","volume":"132","author":"Brosco","year":"2013","journal-title":"Pediatrics"},{"issue":"Suppl","key":"10.1016\/j.gim.2022.12.005_bib5","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ymgme.2011.10.007","article-title":"There is no doubt that the early identification of PKU and prompt and continuous intervention prevents mental retardation in most patients","volume":"104","author":"Blau","year":"2011","journal-title":"Mol Genet Metab"},{"issue":"6139","key":"10.1016\/j.gim.2022.12.005_bib6","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1136\/bmj.2.6139.723","article-title":"Effect of stopping low-phenylalanine diet on intellectual progress of children with phenylketonuria","volume":"2","author":"Smith","year":"1978","journal-title":"Br Med J"},{"issue":"21","key":"10.1016\/j.gim.2022.12.005_bib7","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1056\/NEJM198011203032104","article-title":"Maternal phenylketonuria and hyperphenylalaninemia. An international survey of the outcome of untreated and treated pregnancies","volume":"303","author":"Lenke","year":"1980","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.gim.2022.12.005_bib8","doi-asserted-by":"crossref","first-page":"906","DOI":"10.11124\/JBIES-21-00112","article-title":"PRISMA 2020: a reporting guideline for the next generation of systematic reviews","volume":"19","author":"Brennan","year":"2021","journal-title":"JBI Evid Synth"},{"key":"10.1016\/j.gim.2022.12.005_bib9","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/8904_2012_168","article-title":"A\u00a0systematic review of BH4 (sapropterin) for the adjuvant treatment of phenylketonuria","volume":"8","author":"Lindegren","year":"2013","journal-title":"JIMD Rep"},{"key":"10.1016\/j.gim.2022.12.005_bib10","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.gim.2022.12.005_bib11","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.gim.2022.12.005_bib12","doi-asserted-by":"crossref","first-page":"f1049","DOI":"10.1136\/bmj.f1049","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement","volume":"346","author":"Husereau","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.gim.2022.12.005_bib149","series-title":"R. A langauge and environment for statistical computing. Version 4.1.2 \u201cBird Hippie\"","year":"2021"},{"issue":"4","key":"10.1016\/j.gim.2022.12.005_bib13","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Based Ment Health"},{"issue":"3","key":"10.1016\/j.gim.2022.12.005_bib14","first-page":"1","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J\u00a0Stat Soft"},{"key":"10.1016\/j.gim.2022.12.005_bib15","series-title":"ggplot2: Elegant Graphics for Data Analysis","author":"Wickham","year":"2016"},{"issue":"43","key":"10.1016\/j.gim.2022.12.005_bib16","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.21105\/joss.01686","article-title":"Welcome to the Tidyverse","volume":"4","author":"Wickham","year":"2019","journal-title":"J\u00a0Open Source Softw"},{"issue":"7","key":"10.1016\/j.gim.2022.12.005_bib17","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1002\/ajmg.a.62195","article-title":"Factors that increase risk for poor adherence to phenylketonuria treatment in Brazilian patients","volume":"185","author":"Teruya","year":"2021","journal-title":"Am J Med Genet A"},{"issue":"4","key":"10.1016\/j.gim.2022.12.005_bib18","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1023\/A:1005389110739","article-title":"Adult psychosocial outcome in early-treated phenylketonuria","volume":"20","author":"Ris","year":"1997","journal-title":"J\u00a0Inherit Metab Dis"},{"issue":"4","key":"10.1016\/j.gim.2022.12.005_bib19","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/ana.1226","article-title":"Individual blood-brain barrier phenylalanine transport determines clinical outcome in phenylketonuria","volume":"50","author":"Weglage","year":"2001","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.gim.2022.12.005_bib20","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/00004647-200103000-00011","article-title":"Variability of blood-brain ratios of phenylalanine in typical patients with phenylketonuria","volume":"21","author":"Rupp","year":"2001","journal-title":"J\u00a0Cereb Blood Flow Metab"},{"issue":"3","key":"10.1016\/j.gim.2022.12.005_bib21","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1542\/peds.99.3.345","article-title":"Psychiatric disorders in adult patients with early-treated phenylketonuria","volume":"99","author":"Pietz","year":"1997","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.gim.2022.12.005_bib22","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1080\/13803390600745829","article-title":"A\u00a0neuropsychological profile of off-diet adults with phenylketonuria","volume":"29","author":"Moyle","year":"2007","journal-title":"J\u00a0Clin Exp Neuropsychol"},{"issue":"suppl","key":"10.1016\/j.gim.2022.12.005_bib23","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.ymgme.2011.07.015","article-title":"Neurological complications and behavioral problems in patients with phenylketonuria in a follow-up unit","volume":"104","author":"Gonz\u00e1lez","year":"2011","journal-title":"Mol Genet Metab"},{"issue":"4","key":"10.1016\/j.gim.2022.12.005_bib24","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/s41390-021-01728-8","article-title":"Metabolic control during the neonatal period in phenylketonuria: associations with childhood IQ","volume":"91","author":"Liemburg","year":"2022","journal-title":"Pediatr Res"},{"issue":"1","key":"10.1016\/j.gim.2022.12.005_bib25","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1186\/s13023-019-1225-z","article-title":"Adult cognitive outcomes in phenylketonuria: explaining causes of variability beyond average Phe levels","volume":"14","author":"Romani","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"10.1016\/j.gim.2022.12.005_bib26","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1037\/neu0000336","article-title":"The impact of phenylalanine levels on cognitive outcomes in adults with phenylketonuria: effects across tasks and developmental stages","volume":"31","author":"Romani","year":"2017","journal-title":"Neuropsychology"},{"issue":"2","key":"10.1016\/j.gim.2022.12.005_bib27","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1080\/13803395.2019.1696753","article-title":"Emotional health in early-treated adults with phenylketonuria (PKU): relationship with cognitive abilities and blood phenylalanine","volume":"42","author":"Palermo","year":"2020","journal-title":"J\u00a0Clin Exp Neuropsychol"},{"issue":"Suppl 1","key":"10.1016\/j.gim.2022.12.005_bib28","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1007\/PL00014260","article-title":"Care of the adult with phenylketonuria","volume":"155","author":"Koch","year":"1996","journal-title":"Eur J Pediatr"},{"issue":"5","key":"10.1016\/j.gim.2022.12.005_bib29","first-page":"539","article-title":"Treated phenylketonuria: intelligence and blood phenylalanine levels","volume":"75","author":"Fuller","year":"1971","journal-title":"Am J Ment Defic"},{"issue":"2","key":"10.1016\/j.gim.2022.12.005_bib30","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1148\/radiology.177.2.2217781","article-title":"Phenylketonuria: MR imaging of the brain with clinical correlation","volume":"177","author":"Pearsen","year":"1990","journal-title":"Radiology"},{"issue":"12","key":"10.1016\/j.gim.2022.12.005_bib31","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1007\/BF01957228","article-title":"White matter abnormalities in patients with treated hyperphenylalaninaemia: magnetic resonance relaxometry and proton spectroscopy findings","volume":"152","author":"Bick","year":"1993","journal-title":"Eur J Pediatr"},{"issue":"1","key":"10.1016\/j.gim.2022.12.005_bib32","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13023-020-01668-2","article-title":"The effect of improved dietary control on cognitive and psychiatric functioning in adults with phenylketonuria: the ReDAPT study","volume":"16","author":"Burgess","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"Suppl 2","key":"10.1016\/j.gim.2022.12.005_bib33","doi-asserted-by":"crossref","first-page":"S415","DOI":"10.1007\/s10545-008-0978-7","article-title":"Quality of life in noncompliant adults with phenylketonuria after resumption of the diet","volume":"31","author":"Bik-Multanowski","year":"2008","journal-title":"J Inherit Metab Dis"},{"issue":"9","key":"10.1016\/j.gim.2022.12.005_bib34","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.3390\/nu11092035","article-title":"Improved eating behaviour and nutrient intake in noncompliant patients with phenylketonuria after reintroducing a protein substitute: observations from a multicentre study","volume":"11","author":"Green","year":"2019","journal-title":"Nutrients"},{"issue":"4","key":"10.1016\/j.gim.2022.12.005_bib35","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.neurol.2013.09.012","article-title":"Progressive neuropsychiatric manifestations of phenylketonuria in adulthood","volume":"170","author":"Daelman","year":"2014","journal-title":"Rev Neurol (Paris)"},{"issue":"5","key":"10.1016\/j.gim.2022.12.005_bib36","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s13312-015-0644-8","article-title":"Factors influencing verbal intelligence and spoken language in children with phenylketonuria","volume":"52","author":"Soleymani","year":"2015","journal-title":"Indian Pediatr"},{"issue":"7","key":"10.1016\/j.gim.2022.12.005_bib37","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1177\/0883073815623636","article-title":"Autism in phenylketonuria patients: from clinical presentation to molecular defects","volume":"31","author":"Khemir","year":"2016","journal-title":"J\u00a0Child Neurol"},{"issue":"Pt 1","key":"10.1016\/j.gim.2022.12.005_bib38","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1046\/j.1365-2788.1999.43120176.x","article-title":"Economic impact of feeding a phenylalanine-restricted diet to adults with previously untreated phenylketonuria","volume":"43","author":"Brown","year":"1999","journal-title":"J\u00a0Intellect Disabil Res"},{"issue":"4","key":"10.1016\/j.gim.2022.12.005_bib39","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1023\/B:BOLI.0000037351.10132.99","article-title":"Efficiency of long-term tetrahydrobiopterin monotherapy in phenylketonuria","volume":"27","author":"Steinfeld","year":"2004","journal-title":"J\u00a0Inherit Metab Dis"},{"issue":"5","key":"10.1016\/j.gim.2022.12.005_bib40","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/gim.2014.109","article-title":"Long-term developmental progression in infants and young children taking sapropterin for phenylketonuria: a two-year analysis of safety and efficacy","volume":"17","author":"Longo","year":"2015","journal-title":"Genet Med"},{"issue":"5","key":"10.1016\/j.gim.2022.12.005_bib41","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1007\/s10545-007-0605-z","article-title":"The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): a phase II, multicentre, open-label, screening study","volume":"30","author":"Burton","year":"2007","journal-title":"J\u00a0Inherit Metab Dis"},{"issue":"3","key":"10.1016\/j.gim.2022.12.005_bib42","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ymgme.2014.11.011","article-title":"A\u00a0randomized, placebo-controlled, double-blind study of sapropterin to treat ADHD symptoms and executive function impairment in children and adults with sapropterin-responsive phenylketonuria","volume":"114","author":"Burton","year":"2015","journal-title":"Mol Genet Metab"},{"issue":"6","key":"10.1016\/j.gim.2022.12.005_bib43","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/apa.13799","article-title":"Sapropterin treatment does not enhance the health-related quality of life of patients with phenylketonuria and their parents","volume":"106","author":"Feldmann","year":"2017","journal-title":"Acta Paediatr"},{"issue":"5","key":"10.1016\/j.gim.2022.12.005_bib44","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s10545-014-9716-5","article-title":"Use of sapropterin dihydrochloride in maternal phenylketonuria. A European experience of eight cases","volume":"37","author":"Feillet","year":"2014","journal-title":"J\u00a0Inherit Metab Dis"},{"issue":"1","key":"10.1016\/j.gim.2022.12.005_bib45","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ymgme.2014.02.016","article-title":"Sapropterin dihydrochloride use in pregnant women with phenylketonuria: an interim report of the PKU MOMS sub-registry","volume":"112","author":"Grange","year":"2014","journal-title":"Mol Genet Metab"},{"issue":"22","key":"10.1016\/j.gim.2022.12.005_bib46","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1002\/ajmg.a.32562","article-title":"Safety and efficacy of 22 weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuria","volume":"146A","author":"Lee","year":"2008","journal-title":"Am J Med Genet A"},{"issue":"9586","key":"10.1016\/j.gim.2022.12.005_bib47","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0140-6736(07)61234-3","article-title":"Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study","volume":"370","author":"Levy","year":"2007","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.gim.2022.12.005_bib48","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s13023-021-01968-1","article-title":"Long-term efficacy and safety of sapropterin in patients who initiated sapropterin at < 4 years of age with phenylketonuria: results of the 3-year extension of the SPARK open-label, multicentre, randomised phase IIIb trial","volume":"16","author":"Muntau","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"Suppl 1","key":"10.1016\/j.gim.2022.12.005_bib49","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1016\/j.ymgme.2005.06.026","article-title":"Long-term treatment of patients with mild and classical phenylketonuria by tetrahydrobiopterin","volume":"86","author":"Trefz","year":"2005","journal-title":"Mol Genet Metab"},{"issue":"2","key":"10.1016\/j.gim.2022.12.005_bib50","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ymgme.2021.01.001","article-title":"Long-term preservation of intellectual functioning in sapropterin-treated infants and young children with phenylketonuria: a seven-year analysis","volume":"132","author":"Waisbren","year":"2021","journal-title":"Mol Genet Metab"},{"issue":"2","key":"10.1016\/j.gim.2022.12.005_bib51","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ymgme.2011.10.014","article-title":"START, a double blind, placebo-controlled pharmacogenetic test of responsiveness to sapropterin dihydrochloride in phenylketonuria patients","volume":"105","author":"Utz","year":"2012","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.1016\/j.gim.2022.12.005_bib52","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ymgme.2021.02.008","article-title":"Effect of BH4 on blood phenylalanine and tyrosine variations in patients with phenylketonuria","volume":"133","author":"van Wegberg","year":"2021","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.1016\/j.gim.2022.12.005_bib53","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s13023-018-0923-2","article-title":"One-year follow-up of B vitamin and iron status in patients with phenylketonuria provided tetrahydrobiopterin (BH4)","volume":"13","author":"Brantley","year":"2018","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"10.1016\/j.gim.2022.12.005_bib54","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s10545-011-9439-9","article-title":"Decreased functional brain connectivity in individuals with early-treated phenylketonuria: evidence from resting state fMRI","volume":"35","author":"Christ","year":"2012","journal-title":"J\u00a0Inherit Metab Dis"},{"issue":"1-2","key":"10.1016\/j.gim.2022.12.005_bib55","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ymgme.2018.07.002","article-title":"The impact of metabolic control and tetrahydrobiopterin treatment on health related quality of life of patients with early-treated phenylketonuria: a PKU-COBESO study","volume":"125","author":"Huijbregts","year":"2018","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.gim.2022.12.005_bib56","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ymgmr.2015.07.002","article-title":"The challenge of long-term tetrahydrobiopterin (BH4) therapy in phenylketonuria: effects on metabolic control, nutritional habits and nutrient supply","volume":"4","author":"Thiele","year":"2015","journal-title":"Mol Genet Metab Rep"},{"issue":"5","key":"10.1016\/j.gim.2022.12.005_bib57","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jpeds.2008.11.040","article-title":"Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study","volume":"154","author":"Trefz","year":"2009","journal-title":"J\u00a0Pediatr"},{"issue":"12","key":"10.1016\/j.gim.2022.12.005_bib58","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/j.metabol.2012.07.015","article-title":"New evidence for assessing tetrahydrobiopterin (BH(4)) responsiveness","volume":"61","author":"Bueno","year":"2012","journal-title":"Metabolism"},{"issue":"4","key":"10.1016\/j.gim.2022.12.005_bib59","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ymgme.2018.06.009","article-title":"Anthropomorphic measurements and nutritional biomarkers after 5 years of BH4 treatment in phenylketonuria patients","volume":"124","author":"Evers","year":"2018","journal-title":"Mol Genet Metab"},{"issue":"1-2","key":"10.1016\/j.gim.2022.12.005_bib60","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ymgme.2011.05.011","article-title":"Effect of tetrahydrobiopterin on Phe\/Tyr ratios and variation in Phe levels in tetrahydrobiopterin responsive PKU patients","volume":"104","author":"Humphrey","year":"2011","journal-title":"Mol Genet Metab"},{"issue":"6","key":"10.1016\/j.gim.2022.12.005_bib61","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s10545-012-9458-1","article-title":"Tetrahydrobiopterin (BH4) in PKU: effect on dietary treatment, metabolic control, and quality of life","volume":"35","author":"Ziesch","year":"2012","journal-title":"J\u00a0Inherit Metab Dis"},{"issue":"6","key":"10.1016\/j.gim.2022.12.005_bib62","doi-asserted-by":"crossref","first-page":"e1881","DOI":"10.1542\/peds.2012-3291","article-title":"Long-term follow-up and outcome of phenylketonuria patients on sapropterin: a retrospective study","volume":"131","author":"Keil","year":"2013","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.gim.2022.12.005_bib63","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s10545-010-9224-1","article-title":"BH(4) therapy impacts the nutrition status and intake in children with phenylketonuria: 2-year follow-up","volume":"33","author":"Singh","year":"2010","journal-title":"J\u00a0Inherit Metab Dis"},{"issue":"5","key":"10.1016\/j.gim.2022.12.005_bib64","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ejpn.2019.08.005","article-title":"Prevalence of sleep disorders in early-treated phenylketonuric children and adolescents. Correlation with dopamine and serotonin status","volume":"23","author":"Gassi\u00f3","year":"2019","journal-title":"Eur J Paediatr Neurol"},{"issue":"Suppl 1","key":"10.1016\/j.gim.2022.12.005_bib65","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1016\/j.ymgme.2005.05.013","article-title":"Long-term treatment with tetrahydrobiopterin increases phenylalanine tolerance in children with severe phenotype of phenylketonuria","volume":"86","author":"Hennermann","year":"2005","journal-title":"Mol Genet Metab"},{"issue":"Suppl 1","key":"10.1016\/j.gim.2022.12.005_bib66","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1016\/j.ymgme.2005.05.014","article-title":"Clinical and nutritional evaluation of phenylketonuric patients on tetrahydrobiopterin monotherapy","volume":"86","author":"Lambruschini","year":"2005","journal-title":"Mol Genet Metab"},{"issue":"4","key":"10.1016\/j.gim.2022.12.005_bib67","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ymgme.2013.05.017","article-title":"Tetrahydrobiopterin therapy vs phenylalanine-restricted diet: impact on growth in PKU","volume":"109","author":"Ald\u00e1miz-Echevarr\u00eda","year":"2013","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.1016\/j.gim.2022.12.005_bib68","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ymgme.2015.03.007","article-title":"6R-tetrahydrobiopterin treated PKU patients below 4 years of age: physical outcomes, nutrition and genotype","volume":"115","author":"Ald\u00e1miz-Echevarr\u00eda","year":"2015","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.gim.2022.12.005_bib69","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13023-015-0227-8","article-title":"Long-term follow-up of patients with phenylketonuria treated with tetrahydrobiopterin: a seven years experience","volume":"10","author":"Scala","year":"2015","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.gim.2022.12.005_bib70","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13023-017-0600-x","article-title":"Efficacy, safety and population pharmacokinetics of sapropterin in PKU patients <4 years: results from the SPARK open-label, multicentre, randomized phase IIIb trial","volume":"12","author":"Muntau","year":"2017","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"10.1016\/j.gim.2022.12.005_bib71","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ymgme.2012.11.012","article-title":"Use of sapropterin in the management of phenylketonuria: seven case reports","volume":"108","author":"Gokmen Ozel","year":"2013","journal-title":"Mol Genet Metab"},{"issue":"Suppl","key":"10.1016\/j.gim.2022.12.005_bib72","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.ymgme.2013.09.015","article-title":"Evaluation of quality of life in PKU before and after introducing tetrahydrobiopterin (BH4); a prospective multi-center cohort study","volume":"110","author":"Demirdas","year":"2013","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.gim.2022.12.005_bib73","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/1477-7525-11-218","article-title":"Longitudinal quality of life analysis in a phenylketonuria cohort provided sapropterin dihydrochloride","volume":"11","author":"Douglas","year":"2013","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"10.1016\/j.gim.2022.12.005_bib74","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ymgme.2014.10.013","article-title":"Adherence to tetrahydrobiopterin therapy in patients with phenylketonuria","volume":"114","author":"Rohr","year":"2015","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.gim.2022.12.005_bib75","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.nicl.2013.08.012","article-title":"The effects of tetrahydrobiopterin (BH4) treatment on brain function in individuals with phenylketonuria","volume":"3","author":"Christ","year":"2013","journal-title":"NeuroImage Clin"},{"issue":"3","key":"10.1016\/j.gim.2022.12.005_bib76","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ymgme.2013.07.010","article-title":"White matter integrity and executive abilities following treatment with tetrahydrobiopterin (BH4) in individuals with phenylketonuria","volume":"110","author":"White","year":"2013","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.1016\/j.gim.2022.12.005_bib77","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ymgme.2018.03.003","article-title":"Pegvaliase for the treatment of phenylketonuria: A pivotal, double-blind randomized discontinuation Phase 3 clinical trial","volume":"124","author":"Harding","year":"2018","journal-title":"Mol Genet Metab"},{"issue":"4","key":"10.1016\/j.gim.2022.12.005_bib78","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ymgme.2021.06.002","article-title":"Nutrition status of adults with phenylketonuria treated with pegvaliase","volume":"133","author":"Viau","year":"2021","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.gim.2022.12.005_bib79","article-title":"First 1.5 years of pegvaliase clinic: experiences and outcomes","volume":"24","author":"Sacharow","year":"2020","journal-title":"Mol Genet Metab Rep"},{"issue":"1","key":"10.1016\/j.gim.2022.12.005_bib80","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ymgme.2018.03.006","article-title":"Pegvaliase for the treatment of phenylketonuria: results of a long-term phase 3 clinical trial program (PRISM)","volume":"124","author":"Thomas","year":"2018","journal-title":"Mol Genet Metab"},{"issue":"1-2","key":"10.1016\/j.gim.2022.12.005_bib81","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ymgme.2019.07.018","article-title":"Long-term comparative effectiveness of pegvaliase versus standard of care comparators in adults with phenylketonuria","volume":"128","author":"Zori","year":"2019","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.1016\/j.gim.2022.12.005_bib82","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13023-018-0858-7","article-title":"Long-term safety and efficacy of pegvaliase for the treatment of phenylketonuria in adults: combined phase 2 outcomes through PAL-003 extension study","volume":"13","author":"Longo","year":"2018","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"10.1016\/j.gim.2022.12.005_bib83","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ymgme.2021.05.006","article-title":"Palynziq clinic: one year and 43 patients later","volume":"133","author":"Lah","year":"2021","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.1016\/j.gim.2022.12.005_bib84","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ymgme.2007.02.002","article-title":"The effects of large neutral amino acid supplements in PKU: an MRS and neuropsychological study","volume":"91","author":"Schindeler","year":"2007","journal-title":"Mol Genet Metab"},{"issue":"5","key":"10.1016\/j.gim.2022.12.005_bib85","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jpeds.2012.10.015","article-title":"Large neutral amino acid supplementation increases melatonin synthesis in phenylketonuria: a new biomarker","volume":"162","author":"Yano","year":"2013","journal-title":"J\u00a0Pediatr"},{"issue":"8","key":"10.1016\/j.gim.2022.12.005_bib86","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1172\/JCI5017","article-title":"Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria","volume":"103","author":"Pietz","year":"1999","journal-title":"J\u00a0Clin Invest"},{"issue":"2","key":"10.1016\/j.gim.2022.12.005_bib87","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1096-7192(03)00078-7","article-title":"Large neutral amino acid therapy and phenylketonuria: a promising approach to treatment","volume":"79","author":"Koch","year":"2003","journal-title":"Mol Genet Metab"},{"issue":"7","key":"10.1016\/j.gim.2022.12.005_bib88","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.3390\/nu12072078","article-title":"The impact of a slow-release large neutral amino acids supplement on treatment adherence in adult patients with phenylketonuria","volume":"12","author":"Burlina","year":"2020","journal-title":"Nutrients"},{"issue":"10","key":"10.1016\/j.gim.2022.12.005_bib89","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.3390\/nu11102541","article-title":"Large neutral amino acid therapy increases tyrosine levels in adult patients with phenylketonuria: a long-term study","volume":"11","author":"Burlina","year":"2019","journal-title":"Nutrients"},{"issue":"4","key":"10.1016\/j.gim.2022.12.005_bib90","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.3390\/nu12041092","article-title":"Large neutral amino acids (LNAAs) supplementation improves neuropsychological performances in adult patients with phenylketonuria","volume":"12","author":"Scala","year":"2020","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/j.gim.2022.12.005_bib91","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/ejcn.2016.166","article-title":"Long-term treatment of phenylketonuria with a new medical food containing large neutral amino acids","volume":"71","author":"Concolino","year":"2017","journal-title":"Eur J Clin Nutr"},{"issue":"1","key":"10.1016\/j.gim.2022.12.005_bib92","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1469-8749.1985.tb04522.x","article-title":"Preliminary support for the oral administration of valine, isoleucine and leucine for phenylketonuria","volume":"27","author":"Jordan","year":"1985","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.gim.2022.12.005_bib93","article-title":"The use of glycomacropeptide in dietary management of phenylketonuria","volume":"2016","author":"Zaki","year":"2016","journal-title":"J\u00a0Nutr Metab"},{"issue":"2","key":"10.1016\/j.gim.2022.12.005_bib94","first-page":"194","article-title":"Metabolomic markers of essential fatty acids, carnitine, and cholesterol metabolism in adults and adolescents with phenylketonuria","volume":"148","author":"Stroup","year":"2018","journal-title":"J\u00a0Nutr"},{"issue":"4","key":"10.1016\/j.gim.2022.12.005_bib95","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ymgme.2010.04.003","article-title":"Breakfast with glycomacropeptide compared with amino acids suppresses plasma ghrelin levels in individuals with phenylketonuria","volume":"100","author":"MacLeod","year":"2010","journal-title":"Mol Genet Metab"},{"issue":"10","key":"10.1016\/j.gim.2022.12.005_bib96","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1038\/ejcn.2017.38","article-title":"Nutritional status in patients with phenylketonuria using glycomacropeptide as their major protein source","volume":"71","author":"Pinto","year":"2017","journal-title":"Eur J Clin Nutr"},{"issue":"1","key":"10.1016\/j.gim.2022.12.005_bib97","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13023-019-1011-y","article-title":"Glycomacropeptide: long-term use and impact on blood phenylalanine, growth and nutritional status in children with PKU","volume":"14","author":"Daly","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"10.1016\/j.gim.2022.12.005_bib98","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.3390\/nu12092704","article-title":"The impact of the use of glycomacropeptide on satiety and dietary intake in phenylketonuria","volume":"12","author":"Daly","year":"2020","journal-title":"Nutrients"},{"issue":"6","key":"10.1016\/j.gim.2022.12.005_bib99","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.3390\/nu13062075","article-title":"A\u00a0three-year longitudinal study comparing bone mass, density, and geometry measured by DXA, pQCT, and bone turnover markers in children with PKU taking L-amino acid or glycomacropeptide protein substitutes","volume":"13","author":"Daly","year":"2021","journal-title":"Nutrients"},{"issue":"4","key":"10.1016\/j.gim.2022.12.005_bib100","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.3390\/nu13041323","article-title":"Growth and body composition in PKU children-a three-year prospective study comparing the effects of L-amino acid to glycomacropeptide protein substitutes","volume":"13","author":"Daly","year":"2021","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/j.gim.2022.12.005_bib101","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13023-021-01721-8","article-title":"Continuous use of glycomacropeptide in the nutritional management of patients with phenylketonuria: a clinical perspective","volume":"16","author":"Pena","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.gim.2022.12.005_bib102","doi-asserted-by":"crossref","DOI":"10.1088\/1752-7163\/ab4097","article-title":"Investigation of paediatric PKU breath malodour, comparing glycomacropeptide with phenylalanine free L-amino acid supplements","volume":"14","author":"Tiele","year":"2019","journal-title":"J Breath Res"},{"issue":"2","key":"10.1016\/j.gim.2022.12.005_bib103","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3945\/ajcn.116.135293","article-title":"Glycomacropeptide for nutritional management of phenylketonuria: a randomized, controlled, crossover trial","volume":"104","author":"Ney","year":"2016","journal-title":"Am J Clin Nutr"},{"issue":"3","key":"10.1016\/j.gim.2022.12.005_bib104","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3390\/nu11030520","article-title":"The effect of glycomacropeptide versus amino acids on phenylalanine and tyrosine variability over 24 hours in children with PKU: a randomized controlled trial","volume":"11","author":"Daly","year":"2019","journal-title":"Nutrients"},{"issue":"8","key":"10.1016\/j.gim.2022.12.005_bib105","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.jand.2012.05.004","article-title":"Food products made with glycomacropeptide, a low-phenylalanine whey protein, provide a new alternative to amino acid-based medical foods for nutrition management of phenylketonuria","volume":"112","author":"van Calcar","year":"2012","journal-title":"J\u00a0Acad Nutr Diet"},{"issue":"4","key":"10.1016\/j.gim.2022.12.005_bib106","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/jhn.12438","article-title":"Glycomacropeptide in children with phenylketonuria: does its phenylalanine content affect blood phenylalanine control?","volume":"30","author":"Daly","year":"2017","journal-title":"J\u00a0Hum Nutr Diet"},{"issue":"4","key":"10.1016\/j.gim.2022.12.005_bib107","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3945\/ajcn.2008.27280","article-title":"Improved nutritional management of phenylketonuria by using a diet containing glycomacropeptide compared with amino acids","volume":"89","author":"van Calcar","year":"2009","journal-title":"Am J Clin Nutr"},{"issue":"8","key":"10.1016\/j.gim.2022.12.005_bib108","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.3390\/nu12082443","article-title":"Preliminary investigation to review if a glycomacropeptide compared to L-amino acid protein substitute alters the pre- and postprandial amino acid profile in children with phenylketonuria","volume":"12","author":"Daly","year":"2020","journal-title":"Nutrients"},{"issue":"8","key":"10.1016\/j.gim.2022.12.005_bib150","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/s42255-021-00430-7","article-title":"Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1\/2a study","volume":"3","author":"Puurunen","year":"2021","journal-title":"Nat Metab"},{"key":"10.1016\/j.gim.2022.12.005_bib109","article-title":"Health economic burden of patients with phenylketonuria (PKU) \u2013 A retrospective study of German health insurance claims data","volume":"27","author":"Trefz","year":"2021","journal-title":"Mol Genet Metab Rep"},{"issue":"1","key":"10.1016\/j.gim.2022.12.005_bib110","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12913-020-5054-5","article-title":"Prevalence, characteristics, and costs of diagnosed homocystinuria, elevated homocysteine, and phenylketonuria in the United States: a retrospective claims-based comparison","volume":"20","author":"Sellos-Moura","year":"2020","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.gim.2022.12.005_bib111","article-title":"The financial and time burden associated with phenylketonuria treatment in the United States","volume":"21","author":"Rose","year":"2019","journal-title":"Mol Genet Metab Rep"},{"issue":"10","key":"10.1016\/j.gim.2022.12.005_bib112","first-page":"1025","article-title":"Characteristics, comorbidities, and use of healthcare resources of patients with phenylketonuria: a population-based study","volume":"22","author":"Darb\u00e0","year":"2019","journal-title":"J\u00a0Med Econ"},{"issue":"4","key":"10.1016\/j.gim.2022.12.005_bib113","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s40261-019-00760-1","article-title":"Admissions and cost of hospitalisation of phenylketonuria: Spanish claims database analysis","volume":"39","author":"Darb\u00e0","year":"2019","journal-title":"Clin Drug Investig"},{"issue":"3","key":"10.1016\/j.gim.2022.12.005_bib114","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ymgme.2018.09.006","article-title":"Prevalence of comorbid conditions among adult patients diagnosed with phenylketonuria","volume":"125","author":"Burton","year":"2018","journal-title":"Mol Genet Metab"},{"issue":"6","key":"10.1016\/j.gim.2022.12.005_bib115","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1365-2788.2012.01568.x","article-title":"Costs and outcomes over 36 years of patients with phenylketonuria who do and do not remain on a phenylalanine-restricted diet","volume":"57","author":"Guest","year":"2013","journal-title":"J\u00a0Intellect Disabil Res"},{"issue":"5","key":"10.1016\/j.gim.2022.12.005_bib116","first-page":"381","article-title":"Newborn screening and treatment of phenylketonuria: projected health outcomes and cost-effectiveness","volume":"8","author":"Chen","year":"2021","journal-title":"Children (Basel)"},{"issue":"5","key":"10.1016\/j.gim.2022.12.005_bib117","first-page":"493","article-title":"Cost-utility analysis of neonatal screening program, Shiraz University of Medical Sciences, Shiraz, Iran, 2010","volume":"23","author":"Hatam","year":"2013","journal-title":"Iran J Pediatr"},{"key":"10.1016\/j.gim.2022.12.005_bib118","article-title":"Unmet needs in PKU and the disease impact on the day-to-day lives in Brazil: results from a survey with 228 patients and their caregivers","volume":"24","author":"Martins","year":"2020","journal-title":"Mol Genet Metab Rep"},{"issue":"3","key":"10.1016\/j.gim.2022.12.005_bib119","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ymgme.2013.05.003","article-title":"The time consuming nature of phenylketonuria: a cross-sectional study investigating time burden and costs of phenylketonuria in the Netherlands","volume":"109","author":"Eijgelshoven","year":"2013","journal-title":"Mol Genet Metab"},{"issue":"4","key":"10.1016\/j.gim.2022.12.005_bib120","first-page":"509","article-title":"Retrospective study of patients with hyperphenylalaninemia\u2014experience from a tertiary care center in Pakistan","volume":"69","author":"Ahmed","year":"2019","journal-title":"J\u00a0Pak Med Assoc"},{"key":"10.1016\/j.gim.2022.12.005_bib121","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymgmr.2016.08.008","article-title":"The personal burden for caregivers of children with phenylketonuria: a cross-sectional study investigating time burden and costs in the UK","volume":"9","author":"MacDonald","year":"2016","journal-title":"Mol Genet Metab Rep"},{"issue":"3","key":"10.1016\/j.gim.2022.12.005_bib122","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s10545-016-9995-0","article-title":"Household financial burden of phenylketonuria and its impact on treatment in China: a cross-sectional study","volume":"40","author":"Wang","year":"2017","journal-title":"J\u00a0Inherit Metab Dis"},{"issue":"4","key":"10.1016\/j.gim.2022.12.005_bib123","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000510260","article-title":"Everyday life, dietary practices, and health conditions of adult PKU patients: a multicenter, cross-sectional study","volume":"76","author":"Klimek","year":"2020","journal-title":"Ann Nutr Metab"},{"issue":"1","key":"10.1016\/j.gim.2022.12.005_bib124","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/ejcn.2017.102","article-title":"Dietary patterns, cost and compliance with low-protein diet of phenylketonuria and other inherited metabolic diseases","volume":"72","author":"Ml\u010doch","year":"2018","journal-title":"Eur J Clin Nutr"},{"issue":"3","key":"10.1016\/j.gim.2022.12.005_bib125","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ymgme.2011.12.004","article-title":"Diet in phenylketonuria: a snapshot of special dietary costs and reimbursement systems in 10 international centers","volume":"105","author":"Belanger-Quintana","year":"2012","journal-title":"Mol Genet Metab"},{"issue":"2-3","key":"10.1016\/j.gim.2022.12.005_bib126","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ymgme.2010.05.017","article-title":"Suboptimal outcomes in patients with PKU treated early with diet\u00a0alone: revisiting the evidence","volume":"101","author":"Enns","year":"2010","journal-title":"Mol Genet Metab"},{"issue":"4","key":"10.1016\/j.gim.2022.12.005_bib127","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1590\/S2179-64912012000400016","article-title":"Breastfeeding follow-up in the treatment of children with phenylketonuria","volume":"24","author":"Lam\u00f4nica","year":"2012","journal-title":"J\u00a0Soc Bras Fonoaudiol"},{"issue":"1","key":"10.1016\/j.gim.2022.12.005_bib128","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.pedn.2014.05.003","article-title":"Challenges to breastfeeding infants with phenylketonuria","volume":"30","author":"Banta-Wright","year":"2015","journal-title":"J\u00a0Pediatr Nurs"},{"issue":"3","key":"10.1016\/j.gim.2022.12.005_bib129","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1089\/bfm.2013.0092","article-title":"Breastfeeding infants with phenylketonuria in the United States and Canada","volume":"9","author":"Banta-Wright","year":"2014","journal-title":"Breastfeed Med"},{"issue":"6","key":"10.1016\/j.gim.2022.12.005_bib130","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/1552-6909.12750","article-title":"Commitment to breastfeeding in the context of phenylketonuria","volume":"44","author":"Banta-Wright","year":"2015","journal-title":"J\u00a0Obstet Gynecol Neonatal Nurs"},{"issue":"3","key":"10.1016\/j.gim.2022.12.005_bib131","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3390\/nu11030529","article-title":"How does feeding development and progression onto solid foods in PKU compare with non-PKU children during weaning?","volume":"11","author":"Evans","year":"2019","journal-title":"Nutrients"},{"issue":"3","key":"10.1016\/j.gim.2022.12.005_bib132","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/jhn.12510","article-title":"Fifteen years of using a second stage protein substitute for weaning in phenylketonuria: a retrospective study","volume":"31","author":"Evans","year":"2018","journal-title":"J\u00a0Hum Nutr Diet"},{"issue":"12","key":"10.1016\/j.gim.2022.12.005_bib133","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.3390\/nu11122857","article-title":"Mealtime anxiety and coping behaviour in parents and children during weaning in PKU: a case-control study","volume":"11","author":"Evans","year":"2019","journal-title":"Nutrients"},{"issue":"3","key":"10.1016\/j.gim.2022.12.005_bib134","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3390\/nu11030552","article-title":"Growth, protein and energy intake in children with PKU taking a weaning protein substitute in the first two years of life: a case-control study","volume":"11","author":"Evans","year":"2019","journal-title":"Nutrients"},{"issue":"7","key":"10.1016\/j.gim.2022.12.005_bib135","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1515\/jpem-2016-0461","article-title":"Improved metabolic control in tetrahydrobiopterin (BH4), responsive phenylketonuria with sapropterin administered in two divided doses vs. a single daily dose","volume":"30","author":"K\u00f6r","year":"2017","journal-title":"J\u00a0Pediatr Endocrinol Metab"},{"key":"10.1016\/j.gim.2022.12.005_bib136","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12986-017-0207-1","article-title":"Phenylketonuria patients\u2019 and their parents\u2019 knowledge and attitudes to the daily diet \u2013 multi-centre study","volume":"14","author":"Witalis","year":"2017","journal-title":"Nutr Metab (Lond)"},{"key":"10.1016\/j.gim.2022.12.005_bib137","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13023-015-0294-x","article-title":"Assessment of the impact of phenylketonuria and its treatment on quality of life of patients and parents from seven European countries","volume":"10","author":"Bosch","year":"2015","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.gim.2022.12.005_bib138","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/cch.12727","article-title":"Psychosocial functioning in children with phenylketonuria: relationships between quality of life and parenting indicators","volume":"46","author":"Morawska","year":"2020","journal-title":"Child Care Health Dev"},{"issue":"3","key":"10.1016\/j.gim.2022.12.005_bib139","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/DBP.0000000000000748","article-title":"Caring for a child with phenylketonuria: parental experiences from a Eurasian country","volume":"41","author":"Zengin Akkus","year":"2020","journal-title":"J\u00a0Dev Behav Pediatr"},{"issue":"7","key":"10.1016\/j.gim.2022.12.005_bib140","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1515\/jpem-2020-0035","article-title":"Quality of life and associated factors in parents of children with late diagnosed phenylketonuria. A cross sectional study in a developing country (Tunisia)","volume":"33","author":"Ben Abdelaziz","year":"2020","journal-title":"J\u00a0Pediatr Endocrinol Metab"},{"issue":"2-3","key":"10.1016\/j.gim.2022.12.005_bib141","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/jcap.12207","article-title":"Stress and quality of life in parents of children with phenylketonuria","volume":"31","author":"Irannejad","year":"2018","journal-title":"J\u00a0Child Adolesc Psychiatr Nurs"},{"issue":"3","key":"10.1016\/j.gim.2022.12.005_bib142","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1515\/jpem-2018-0525","article-title":"The effect of PKU diet on the maternal quality of life and social discrimination in relation to their educational status and place of living","volume":"32","author":"Iakovou","year":"2019","journal-title":"J\u00a0Pediatr Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.gim.2022.12.005_bib143","first-page":"53","article-title":"Effects of empowerment program on the burden of care in mothers of children with phenylketonuria","volume":"13","author":"Rahgoi","year":"2019","journal-title":"Iran J Child Neurol"},{"issue":"2","key":"10.1016\/j.gim.2022.12.005_bib144","first-page":"531","article-title":"Neurological manifestations in adults with phenylketonuria: new cases and review of the literature","volume":"267","author":"Jaulent","year":"2020","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.gim.2022.12.005_bib145","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.2147\/NDT.S176198","article-title":"Clinical and neuropsychological outcomes for children with phenylketonuria in upper Egypt; a single-center study over 5 years","volume":"14","author":"Sadek","year":"2018","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"21","key":"10.1016\/j.gim.2022.12.005_bib146","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1056\/NEJM198311243092101","article-title":"Effects of untreated maternal phenylketonuria and hyperphenylalaninemia on the fetus","volume":"309","author":"Levy","year":"1983","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.gim.2022.12.005_bib147","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0022-3476(87)80500-0","article-title":"New England Maternal PKU Project: prospective study of untreated and treated pregnancies and their outcomes","volume":"110","author":"Rohr","year":"1987","journal-title":"J\u00a0Pediatr"},{"issue":"8","key":"10.1016\/j.gim.2022.12.005_bib148","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"147","author":"von Elm","year":"2007","journal-title":"Ann Intern Med"}],"container-title":["Genetics in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098360022010632?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098360022010632?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T12:18:31Z","timestamp":1730981911000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098360022010632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":150,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1098360022010632"],"URL":"https:\/\/doi.org\/10.1016\/j.gim.2022.12.005","relation":{},"ISSN":["1098-3600"],"issn-type":[{"value":"1098-3600","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phenylalanine hydroxylase deficiency treatment and management: A systematic evidence review of the American College of Medical Genetics and Genomics (ACMG)","name":"articletitle","label":"Article Title"},{"value":"Genetics in Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gim.2022.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American College of Medical Genetics and Genomics. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100358"}}